SRR12696771
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- MYC_TARGETS_V1+0.600
- MYC_TARGETS_V2+0.600
- G2M_CHECKPOINT+0.500
- DNA_REPAIR+0.400
- MTORC1_SIGNALING+0.400
- OXIDATIVE_PHOSPHORYLATION+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
- ANDROGEN_RESPONSE+0.300
Top 10 suppressed
- BILE_ACID_METABOLISM-0.200
- KRAS_SIGNALING_DN-0.200
- HEDGEHOG_SIGNALING-0.100
- HEME_METABOLISM-0.100
- WNT_BETA_CATENIN_SIGNALING-0.100
- APICAL_SURFACE+0.000
- ESTROGEN_RESPONSE_EARLY+0.000
- ESTROGEN_RESPONSE_LATE+0.000
- MYOGENESIS+0.000
- PANCREAS_BETA_CELLS+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 1B940F72-3C90-43C4-9267-185F21D10AC9 | — | — | 0.931 |
| 2 | BS_F6V1Y4QS | Glial-neuronal tumor NOS | — | 0.922 |
| 3 | 61D1FD4D-F0FF-4D89-B26F-C1102685ED9D | — | — | 0.918 |
| 4 | 55E3F1FB-D55D-42F8-A9E1-7828F7BFF595 | — | — | 0.914 |
| 5 | BS_SHJA4MR0 | high-grade glioma | — | 0.913 |
| 6 | 541FDA8B-9FAE-4346-A6FD-C56735C87920 | — | — | 0.913 |
| 7 | 46061E4B-5256-42AD-BA9A-FBCEBE92B09A | — | — | 0.912 |
| 8 | ECCC2F18-409F-41BA-B49F-95B23893B80B | — | — | 0.912 |
| 9 | 769432C5-4BFD-4689-8F43-467010292448 | — | — | 0.911 |
| 10 | 66FF1C46-83F0-4EEC-9871-448C8C7EA3AE | — | — | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |